offerings
Erasca, Corvus, and BioAge Target $500M+ Offerings Amid Biotech Fundraising Surge
Erasca; Corvus; BioAge; biotech offerings; fundraising; public offering
Upstream Biotech Prepares to Join the Wave of Biotech IPOs with Inflammation-Focused Therapies
Biotech IPOs, Upstream Biotech, Inflammation-focused therapies, Biotechnology industry, Public offerings, Healthcare innovation
Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings
Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings